Efficacy of the eradication of Helicobacter pylori infection in patients with chronic urticaria. A placebo-controlled double blind study.
Helicobacter pylori has been involved in the pathogenesis of chronic idiopathic urticaria (CIU) in patients suffering both CIU and H. pylori infection. We selected 49 patients with 13C urea breath test positive, long-lasting CIU and H. pylori infection; 20 remained symptomatic, had positive urease test or H. pylori histologic identification in gastric biopsy material and accepted to participate in a pacebo-controlled treatment trial. They were randomized for a 7-day, double-blind, placebo-controlled H. pylori eradication treatment with amoxicillin, clarithromycin and omeprazol or placebo. H. pylori eradication was assessed by a second 13C urea breath test six weeks after the end of treatment. We observed a significant improvement of more than 70 % of CIU; baseline clinical score was seen in 4 of the 9 (44 %) patients who eradicated H. pylori after active treatment and in 1 of the 7 (12,3 %) of those who did not (p = 0.19). No clinical differences in CIU characteristics were found between patients with and without improvement. No serious adverse effects were observed in either treatment group. We conclude that the eradication of H. pylori may be useful for patients suffering long-lasting CIU and H. pylori infection, although theses results did not reach statistical significance probably owing to the strict conditions of the recruitment.
Gaig
P
P
Allergy Unit. Hospital Universitari Joan XXIII. Institut d'Estudis Avançats. Universitat Rovira i Virgili. Tarragona. Spain. pgaigj@hjxxiii.scs.es
García-Ortega
P
P
Enrique
E
E
Papo
M
M
Quer
J C
JC
Richard
C
C
D000328:Adult; D000658:Amoxicillin / Q000627:therapeutic use; D000799:Angioedema / Q000209:etiology; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D001426:Bacterial Proteins / Q000032:analysis; D001706:Biopsy; D001944:Breath Tests; D002908:Chronic Disease; D017291:Clarithromycin / Q000627:therapeutic use; D004311:Double-Blind Method; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005260:Female; D005753:Gastric Mucosa / Q000737:chemistry / Q000382:microbiology; D005756:Gastritis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D005773:Gastroscopy; D016481:Helicobacter Infections / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000201:enzymology / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use; D011446:Prospective Studies; D016896:Treatment Outcome; D014510:Urease / Q000032:analysis; D014581:Urticaria / Q000209:etiology*
D000897:Anti-Ulcer Agents; D001426:Bacterial Proteins; D000658:Amoxicillin; D014510:Urease; D017291:Clarithromycin; D009853:Omeprazole